CA19-9与胰腺癌放化疗之间的关系  

Relationship between serum CA 19-9 and chemotherapy and radiotherapy in patients with pancreatic cancer

作　　者：邵银剑[1] 王颖杰[2] 

机构地区：[1]安徽医科大学,安徽合肥230032 [2]解放军空军总医院肿瘤放疗科,北京100142

出　　处：《中国医药导报》2013年第23期31-33,共3页China Medical Herald

摘　　要：CA19-9作为胰腺癌最常用的肿瘤标志物,在胰腺癌放化疗中扮演着重要作用。本文通过复习近期文献,旨在为CA19-9在胰腺癌放化疗中的变化以及CA19-9作为胰腺癌放化疗预后的预测因子做一综述:治疗前CA19-9水平升高的胰腺癌患者放化疗后大部分患者的CA19-9水平下降明显;治疗前高水平的CA19-9及治疗后CA19-9下降未达预定幅度的胰腺癌患者预后较差,但这种差异是否有统计学意义尚需进一步证实。The serum CA 19-9 plays an very important role in patients with pancreatic cancer as the most frequent tumor marker.This article aims to describe the change and the predictive value of serum CA19-9 in patients with pancreatic cancer treated with chemotherapy and radiotherapy.The patients with elevated pretreatment serum CA 199 often have a large reduction of serum CA 19-9 after chemotherapy and radiotherapy.The patients with elevated pre treatment serum CA 19-9 have a shorter overall survival time.The patients with serum CA 19-9 reduction did not achieve prospective reduction range after treatment,they also had a poor prognosis,but this difference has not been determined by statistics.

关 键 词：胰腺癌 放射治疗 化学治疗 肿瘤标志物 血清CA19-9 

分 类 号：R735.9[医药卫生—肿瘤]